BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory counterarguments, the inoculation receiver will then seek out supporting information to further strengthen their threatened position. Finally, the held attitude or belief becomes resistant to a stronger attack, hence the medical analogy of a vaccine. Inoculation is a theory developed to strengthen existing attitudes and beliefs while building resistance to future counterarguments. For inoculation to be successful it is crucial that a threat (motivation for resistance) is imposed upon these existing ideas and refutational preemption (ability to build defenses against potential counterarguments) takes place after the inoculation. The argument that is presented through inoculation must be strong enough to initiate